CIMERLI® will be available at 90% discount to Lucentis® (ranibizumab injection)

Permanent Q Code: Q5128

We are pleased to announce that, effective January 5, 2026, CIMERLI® will be offered at a substantially lower Wholesale Acquisition Cost (WAC). This price reduction underscores Sandoz’s ongoing commitment to enhancing patient affordability and access to therapy, while demonstrating responsiveness to evolving market dynamics.


Price Reduction

CIMERLI® WAC will be available at a 90% discount relative to Lucentis WAC. The NDC and Q codes remain unchanged; it is the same product, available in the same two dosage strengths. droAdditional details are provided below:

NDC Code*

Package Description

HCPCS Code

HCPCS Billing Unit

WAC Price

New WAC Price

61314-0625-94

CIMERLI® (ranibizumab-eqrn) INJ

0.5mg/0.05ml single 10mg/mL VL

Q5128

5 Billing Units

$1,360

$200

61314-0624-94

CIMERLI® (ranibizumab-eqrn) INJ

0.3mg/0.05ml single 6mg/mL VL

Q5128

3 Billing Units

$816

$120

*These are the 11-digit NDC codes used for CIMERLI®. The 10-digit NDC codes are: 61314-625-94 and

61314-624-94, respectively. 11-digit NDC codes are used for claims processing and reimbursement.

 

Make CIMERLI accessible without restrictions today

 

All trademarks and trade names are the property of their respective owners.

© 2025 Sandoz Inc.

100 College Road West, Princeton, NJ 08540

www.sandoz.com

MLR-2107-US 12/2025